Therapeutic cannabis use in 2018: where do we stand?

bidmc.harvard.edu.2New York Medical College, Valhalla, NY, USA.3Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada.PMID: 30686389 DOI: 10.1016/S2215-0366(18)30417-6 Share Supplemental Content — View the Original article Partage le savoir

Partage le savoir

Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids.

5-fold, however the mechanisms by which T2D increases dementia risk remain unclear. Evidence suggests that the heightened inflammation and oxidative stress in T2D may lead to disruption of the blood-brain barrier (BBB), which precedes premature cognitive decline. Studies show that vascular-targeted anti-inflammatory treatments protect the BBB by attenuating neuroinflammation, and Read more…

Partage le savoir
error: Content is protected !!